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Pooled human liver microsomes
Recombinant human CYPs
a  b  s  t  r  a  c  t
Profenofos  is  a  direct  acting  phosphorothioate  organophosphorus  (OP)  pesticide  capable  of  inhibiting  -
esterases  such  as  acetylcholinesterase,  butyrylcholinesterase,  and  carboxylesterase.  Profenofos  is  known
to be  detoxiﬁed  to  the  biologically  inactive  metabolite,  4-bromo-2-chlorophenol  (BCP);  however,  limited
data are  available  regarding  the  use of  urinary  BCP  as  an exposure  biomarker  in humans.  A  pilot study
conducted  in  Egyptian  agriculture  workers,  demonstrated  that  urinary  BCP levels  prior  to  applica-
tion  (3.3–30.0  g/g  creatinine)  were  elevated  to 34.5-3566  g/g  creatinine  during the  time workers
were  applying  profenofos  to cotton  ﬁelds.  Subsequently,  the  in  vitro  enzymatic  formation  of BCP  was
examined  using  pooled  human  liver  microsomes  and  recombinant  human  cytochrome  P-450s  (CYPs)
incubated  with  profenofos.  Of the  nine  human  CYPs  studied,  only  CYPs  3A4,  2B6,  and  2C19  were  able
to  metabolize  profenofos  to  BCP.  Kinetic  studies  indicated  that  CYP  2C19  has  the  lowest  Km, 0.516  M
followed  by  2B6  (Km =  1.02  M)  and  3A4  (Km = 18.9 M). The  Vmax for BCP  formation  was 47.9, 25.1, and
19.2 nmol/min/nmol  CYP  for  CYP2B6,  2C19,  and  3A4,  respectively.  Intrinsic  clearance  (Vmax/Km) values
of  48.8,  46.9,  and  1.02  ml/min/nmol  CYP  2C19,  2B6,  and  3A4,  respectively,  indicate  that  CYP2C19  and
CYP2B6  are  primarily  responsible  for  the  detoxiﬁcation  of  profenofos.  These  ﬁndings  support  the  use of
urinary BCP  as a  biomarker  of  exposure  to  profenofos  in humans  and  suggest  polymorphisms  in CYP  2C19
and CYP  2B6  as  potential  biomarkers  of  susceptibility.
© 2013 Published by Elsevier Ireland Ltd.
1. Introduction
Organophosphorus (OP) pesticides are the most commonly used
pesticides throughout the world (Sultatos, 1994). This together
with their potential to produce acute and chronic neurotoxic
responses, positions these compounds as environmental chemicals
of concern to human health. It is generally accepted that inhibi-
tion of acetylcholinesterase (AChE) is the primary mechanism by
which OPs cause acute neurotoxicity (Jamal and Julu, 2002; Farahat
et al., 2003). OP inhibition of AChE, decreases the hydrolysis of
acetylcholine in both central and peripheral cholinergic synapses,
resulting initially in overstimulation of nicotinic and muscarinic
receptors followed by receptor down-regulation on post-synaptic
membranes (Costa, 2006). Acute OP poisoning is generally thought
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to be mediated primarily by overstimulation of receptors sec-
ondary to AChE inhibition, whereas it has been hypothesized that
chronic OP neurotoxicity is due to receptor down-regulation (Costa,
2006). Most OP pesticides require bioactivation by cytochrome P-
450s (CYPs) to form the active oxon metabolite which are potent
cholinesterase inhibitors (Ma and Chambers, 1994).
In contrast to most OP pesticides, the parent form of profenofos
is active, and CYP-mediated metabolism results in oxidative bioac-
tivation and detoxiﬁcation reactions (Wing et al., 1984; Abass et al.,
2007). Profenofos [O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl
phosphorothioate] is a thiophosphate OP pesticide (O P-S-C) that
was developed for pest strains resistant to chlorpyrifos and other
OPs (Gotoh et al., 2001). On average, approximately 775,000
pounds of profenofos is applied to about 5% of the approximately
13,818,000 acres of cotton grown within the United States per year
(U.S. EPA, 2006). It has been classiﬁed as a moderately hazardous
(Toxicity Class II) pesticide by the World Health Organization
(WHO) and it has a moderate level of acute toxicity following oral
and dermal administration (Malghani et al., 2009; Abass et al.,
2007). The use of OP pesticides, such as profenofos and chlorpyrifos,
0300-483X/$ – see front matter ©  2013 Published by Elsevier Ireland Ltd.
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is common in the Nile River delta of Egypt, where agriculture is a
vital component of its national identity and economy. Our group has
previously investigated chlorpyrifos exposure and effects in Egyp-
tian cotton ﬁeld workers by determining the relationship between
chlorpyrifos exposure, as determined by quantiﬁcation of the chlor-
pyrifos speciﬁc urinary metabolite, trichloro-2-pyridinol (TCPy),
and toxicity, as determined by blood cholinesterase activity and
neurobehavioral performance (Farahat et al., 2003, 2010, 2011).
However, biomarkers of profenofos exposure and effect have not
been reported in these agriculture workers or any other occupa-
tional cohort.
Despite the unique ability of profenofos to inhibit cholinesterase
without biotransformation, few studies have investigated profeno-
fos in animal or human models. Animal studies with profenofos
are limited to the WHO  Evaluation of Profenofos (WHO, 2007)
and a study in rats by McDaniel and Moser (2004).  Human
studies are limited to cases of accidental poisoning (Eddleston
et al., 2009; Gotoh et al., 2001), an agricultural worker study
assessing cholinesterase inhibition with chlorpyrifos and profeno-
fos (Lakew and Mekonnen, 1998), and an in vitro study of profenofos
metabolism which measured the formation of the toxicologically
active metabolite, desthiopropylprofenofos and hydroxyprofeno-
fos (Abass et al., 2007).
The current study will focus on the metabolism of profenofos
to its detoxiﬁed metabolite 4-bromo-2-chlorophenol (BCP) (Fig. 1).
BCP is a metabolite unique to profenofos and therefore may  repre-
sent a sensitive and speciﬁc biomarker of exposure for individuals
exposed to profenofos.
2. Materials and methods
2.1. Chemicals
Profenofos (CAS 41198-08-7) and 4-bromo-2-chlorophenol (CAS 3964-56-5)
were purchased from ChemService Inc (West Chester, PA). Tetraisopropyl pyrophos-
phoramide (iso-OMPA; CAS 513-00-8) was purchased from Sigma–Aldrich (St. Louis,
MO)  and Bis(trimethylsilyl)triﬂuoroacetamide (BSTFA) was  obtained from SUPELCO
(Bellefonte, PA). Pooled human liver microsomes (HLM, which contains liver micro-
somes pooled from 50 donors of mixed sex, 20 mg/ml  stock) were obtained from
XenoTech (Lenexa, KS). Recombinant human cytochrome P450s were purchased
from BD Gentest (Woburn, MA).
2.2. Human exposure to profenofos
The human exposure study took place in the Menouﬁa governorate of Egypt,
which is situated in the Nile River delta north of Cairo. Egypt’s Ministry of Agricul-
ture directs the use and application of pesticides in the cotton ﬁelds and employs
workers in one of the following job categories (Farahat et al., 2003, 2010, 2011):
(1) applicator, who applies pesticides with backpack sprayers; (2) technician, who
walks each row with the applicator to direct the path of the applicator; and (3)
engineer, who periodically walks the ﬁeld but more often directs the application
process from the edge of the ﬁeld and oversees the mixing and loading of pesti-
cides into backpack sprayers. Workers applied profenofos to cotton from July 30 to
August 8, 2008. During the summer of 2008, spot urine samples were collected from
workers prior to (July 24) and during the period of application (August 4). Samples
were placed on wet  ice in a cooler and transported to Menouﬁa University (Shebin
El-Kom, Egypt) where they were stored at −20 ◦C until shipped on dry ice to the
University at Buffalo (Buffalo, NY) for analyses.
A  1 ml  aliquot of each urine sample was thawed and mixed prior to the addition
of  50 ng of internal standard 2,4,5 trichlorophenol. Samples were then hydrolyzed
to  free sulfate or glucuronide conjugated BCP (Gotoh et al., 2001) at 80 ◦C for 1 h with
100 l of 12 N HCl, and extracted with 1 ml  of toluene. The toluene extract was then
derivatized with BSTFA at 70 ◦C for 1 h and analyzed by gas chromatography–micro
electron capture detection (GC/ECD) as described in metabolite detection. Creati-
nine concentrations were measured for all workers using the Jaffe reaction (Fabiny
and Ertingshausen, 1971) and urine BCP concentrations are expressed as g/g cre-
atinine.
2.3. In Vitro metabolism
Profenofos (5 M)  was  incubated with pooled human liver microsomes (0.1 mg
protein/ml) in buffer (100 mM Tris–HCl, 5 mM MgCl2, 1 mM EDTA and 50 M iso-
OMPA; pH 7.4) at 37 ◦C in a ﬁnal volume of 0.5 ml.  EDTA was  included to inhibit
-esterases while iso-OMPA was  used to inhibit -esterases (Reiner et al., 1993).
Profenofos was  dissolved in dimethylsulfoxide (DMSO) at a ﬁnal concentration in
the reaction medium of 1%. Incubation conditions were optimized to assure that
the  reaction was  linear with time and protein concentration. All incubations were
initiated by adding 1 mM NADPH and quenched with 50 l of 12 N HCl. Prelimi-
nary studies showed that the hydrolysis step was  not necessary in vitro. For kinetic
studies, pooled human liver microsomes (0.1 mg protein/ml) were incubated with
profenofos (0.1, 0.5, 1, 2.5, 5, 10, 20, 40, and 80 M)  for 2 min. Recombinant human
CYPs 3A4, 2C19, 2B6, 1A1, 1A2, 2C9, 2A6, 2D6, and 2E1 were incubated with pro-
fenofos at a low (1 M)  and high concentration (10 M) to identify CYPs capable of
metabolizing profenofos. Profenofos was then incubated at concentrations of 0.5, 1,
5,  10, 20, 40 and 80 M with the active CYPs (1 nmol/ml) in buffer (100 mM Tris–HCl,
5  mM MgCl2, 1 mM EDTA and 50 M iso-OMPA; pH 7.4) at 37 ◦C with a ﬁnal volume
of  0.5 ml  for 2 min. 25 ng of 2,4,5 trichlorophenol was  added to the mixture followed
by  0.5 ml  of toluene. The ﬁnal mixture was centrifuged followed by extraction of the
supernatant. The samples were then derivatized with BSTFA at 70 ◦C for 1 h and then
analyzed by the GC/ECD.
2.4. Metabolite detection
BCP was  analyzed using a modiﬁcation of the method described by Farahat et al.
(2010).  The method described in Farahat et al. (2010) was  transferred and modiﬁed
to  allow for increased sensitivity of BCP measurement on the GC/ECD. A change in
the detector from GC/MS to GC/ECD required modiﬁcations in the internal standard
as well as derivatizing agent. BCP was identiﬁed using a relative retention time with
internal standard and measured through the use of known concentrations of BCP
standards. The amount of BCP measured using the GC/ECD was comparable to the
amount measured when using GC/MS. The optimized method was used for both
urine and in vitro analyses and described as follows:
Samples were analyzed on an Agilent gas chromatograph model 6890 equipped
with a micro-electron capture detector (ECD) and a capillary column (Rtx-5 with
integra-guard, 65 m ×250 m × 0.25 m nominal) (Restek; Bellefonte, PA). Ultra
pure helium (He) carrier gas was used at a ﬂow rate of 1.2 ml/min. The detector
temperature was set at 325 ◦C with ultra-pure nitrogen (N2) as its make-up gas and
a  ﬂow rate of 60 ml/min. The starting oven temperature of 100 ◦C was held for 1 min
and increased at 10 ◦C/min up to 300 ◦C and then held for 4 min. The injection port
temperature was  set at 250 ◦C with a split ratio of 1:10 and an injection volume of
1  l. Under these conditions, the BCP limit of detection and limit of quantiﬁcation
were 0.16 ng/ml and 0.54 ng/ml respectively (U.S. EPA MDL).
2.5. Data analysis
The kinetic values Vmax and Km were determined by non-linear regression analy-
ses  (enzyme kinetics module of Sigma Plot, SyStat Software Inc., V11) of hyperbolic
plots obeying Michaelis–Menten kinetics. Profenofos concentration (M) was set
as  the independent variable while the rate of formation of BCP (nmol/min/mg pro-
tein or nmol/min/nmol CYP) was the dependent variable. Urinary BCP levels during
the profenofos application period were compared with the levels prior to applica-
tion  using a Wilcoxon Signed Rank Test, with signiﬁcance set at p < 0.05. Km, Vmax,
and intrinsic clearance values for all three recombinant CYPs were compared using
one-way ANOVA with Tukey’s post hoc analysis.
3. Results
3.1. Urinary BCP analysis
The urinary BCP concentrations were quantiﬁed in Egyptian
agriculture workers for each job category prior to (July 24, 2008)
and during the period of profenofos application (August 4, 2008).
Table 1 shows that all workers, regardless of job category, had
detectable amounts of urinary BCP prior to the spray period for
profenofos, indicating that the workers were exposed to low back-
ground levels of profenofos and/or BCP prior to the beginning of the
spray period. The urinary concentrations of BCP increased markedly
during the period of profenofos application. The applicators had the
highest levels of BCP, both prior to and during profenofos applica-
tion, followed by the technicians and engineers (Table 1).
3.2. In Vitro metabolism
Pooled human liver microsomes and recombinant human
CYPs were used to determine kinetic values (Km and Vmax) for
metabolism of profenofos to BCP. A 2 min  incubation time was
determined to be within the linear range of metabolite formation
and BCP was the major metabolite formed when profenofos was
Author's personal copy
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Fig. 1. Metabolism of profenofos to its metabolites hydroxyprofenofos, desethylated profenofos, des-S-propylated profenofos, despropylated profenofos, despropylated
profenofos isomer, and BCP. Figure is an adaptation from ﬁgures presented in Gotoh et al. (2001) and Abass et al. (2007).
Table  1
Urinary BCP concentration (g/g creatinine) in Egyptian agriculture workers prior
to  and during application of profenofos to cotton ﬁelds.
Worker Before spray During spray*
24-July 4-August
Applicator 1 29.6 1027
Applicator 2 30.0 3566
Applicator 3 16.5 974
Technician 1 13.4 62.1
Technician 2 3.27 41.2
Technician 3 3.79 172
Engineer 1 3.56 80.8
Engineer 2 4.24 42.8
Engineer 3 11.2 34.5
* BCP levels during spray period were signiﬁcantly different from levels prior to
spraying period using a Wilcoxon signed rank test (p-value = 0.008).
incubated with pooled HLM or recombinant human CYPs. A plot
of the rate of BCP formation at various profenofos concentrations
utilizing pooled HLM was used to derive Michaelis–Menten kinetic
parameters (Fig. 2). The Km and Vmax values were 0.956 M and
Fig. 2. Michaelis–Menten kinetic parameters were derived from the plot illustrating
the relationship between BCP formation and profenofos (substrate) concentration
using pooled human liver microsomes. Data are presented as the mean ± SEM (n = 3
different experiments).
Table 2
Kinetics of profenofos metabolism.






Pooled HLM 0.96 ± 0.21 2.92 ± 0.12 3.11 ± 0.56





Pooled HLM 0.96 ± 0.21 6.21 ± 0.12 8.74 ± 0.56
CYP 3A4 18.9 ± 3.48* 19.2 ± 1.32 1.02 ± 0.11*
CYP 2B6 1.02 ± 0.13 47.9 ± 1.20* 46.9 ± 1.93
CYP 2C19 0.52 ± 0.09 25.1 ± 0.76 48.8 ± 2.99
Km, Vmax, and the intrinsic clearance of profenofos metabolism were determined
using pooled human liver microsomes (HLM) and recombinant human CYPs 3A4,
2B6, and 2C19. Data are presented as the mean ± SEM (n = 3 separate experiments).
* p < 0.0005 compared with the other two CYPs determined by one-way ANOVA
with Tukey’s post hoc analysis.
2.92 nmol/min/mg respectively, with an intrinsic clearance (CLint)
of 3.11 ml/min/mg (Table 2).
Individual human recombinant cytochrome P450 enzymes were
used to screen the speciﬁc CYPs which were capable of metab-
olizing profenofos to BCP. CYPs 3A4, 2B6, and 2C19 were the
most active in metabolizing profenofos at either 1 M or 10 M
to BCP (Fig. 3). Kinetic parameters for profenofos metabolism were
obtained from Michaelis–Menten plots illustrating the formation
Fig. 3. Differential activity of speciﬁc recombinant human CYPs for biotransforma-
tion of profenofos at 1 (black) or 10 (gray) M to BCP. CYPs 3A4, 2B6, and 2C19
produced the most BCP per minute per nmole of CYP.
Author's personal copy
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Fig. 4. Michaelis–Menten kinetic parameters were derived from the plot illustrating the relationship between BCP formation and profenofos (substrate) concentration using
recombinant human CYP 3A4, 2B6, and 2C19 (panel a, b, and c respectively). Data are presented as the mean ± SEM (n = 3 three different experiments).
of BCP by CYPs 3A4, 2B6, and 2C19 (Fig. 4a–c) and are shown
in Table 2. The rank order of Km was CYP 2C19 (0.52 M)  > CYP
2B6 (1.02 M)  > CYP 3A4 (18.9 M).  The rank order of Vmax was
CYP 2B6 (47.9 nmol BCP/min/nmol CYP) > CYP 2C19 (25.1 nmol
BCP/min/nmol CYP) > CYP 3A4 (19.2 nmol BCP/min/nmol CYP).
From these two kinetic parameters, the rank order of CLint was
CYP 2C19 (48.8 ml/min/nmol CYP) ≥ CYP 2B6 (46.9 ml/min/nmol
CYP) > CYP 3A4 (1.02 ml/min/nmol CYP) (Table 2).
4. Discussion
This is among the ﬁrst studies to assess the occupational expo-
sure of agriculture workers to profenofos using urinary BCP levels as
a sensitive and speciﬁc biomarker of profenofos exposure. Egyptian
cotton ﬁeld workers had a wide range of urinary BCP concentra-
tions during the period of profenofos application to cotton ﬁelds,
with the applicators exhibiting the highest concentrations. This is
consistent with their greater potential for exposure to profenofos,
and the general lack of personal protective equipment use amongst
these workers, which allows for direct contact of the skin with
spray residue containing profenofos (Fenske et al., 2012). Similar
ﬁndings were previously reported in the same workers exposed to
chlorpyrifos, with applicators exhibiting the highest level of uri-
nary TCPy, followed by technicians and engineers (Farahat et al.,
2010, 2011). Since BCP is a metabolite speciﬁc to profenofos, it was
somewhat surprising to ﬁnd low levels of urinary BCP prior to the
period of profenofos application. The occasional, non-occupational
use of pesticides at home and pesticide residues on food crops may
account for the elevated levels of BCP in workers prior to the start
of profenofos spray periods on cotton ﬁelds. Nonetheless, work-
ers in all three job categories, but especially the applicators, had a
marked increase in urinary BCP levels associated with the period of
profenofos application. This observation supports BCP as a sensitive
and speciﬁc biomarker of profenofos exposure.
Prior studies of profenofos metabolism reported the bioactiva-
tion of profenofos to the toxic metabolites desthipropylprofenofos,
and hydroxyprofenofos in rat, mouse, and human liver frac-
tions (Abass et al., 2007). Our study is the ﬁrst to assess the
in vitro metabolism of profenofos to the detoxiﬁed metabolite
BCP by human liver microsomes and puriﬁed human recombinant
CYPs.
Our screen of nine recombinant human CYPs identiﬁed CYPs
3A4, 2B6, and 2C19 as three enzymes capable of detoxifying pro-
fenofos to BCP. Michaelis–Menten kinetic parameters for each
enzyme provided an estimate of Km, Vmax, and the metabolic
efﬁciency of each enzyme expressed as the intrinsic clearance
(Vmax/Km). While all three CYPs were capable of catalyzing the for-
mation of BCP, CYPs 2C19 and 2B6 had the highest afﬁnity with
Km values of 0.52 and 1.02 M,  respectively, in contrast to CYP3A4,
which exhibited a Km of 18.9 M.  The relative efﬁciency of each
enzyme for profenofos metabolism, as measured by intrinsic clear-
ance, indicates that CYP 2B6 and 2C19 are the primary enzymes
responsible for the detoxiﬁcation of profenofos.
Knowledge of the in vitro metabolism of profenofos to BCP has
signiﬁcant potential to inform in vivo studies that use urinary BCP as
a biomarker of exposure to profenofos. Individual variability in uri-
nary BCP excretion may  not only be due to differences in exposure
to profenofos, but may  also be inﬂuenced by genetic differences
in CYP2B6 and CYP2C19, which are highly polymorphic (Hodgson
and Rose, 2007; Zanger et al., 2007; Goldstein et al., 1997; Crane
et al., 2012). Furthermore, serial and/or combined exposures to
multiple pesticides have potential to alter enzyme activities and
Author's personal copy
O.A. Dadson et al. / Toxicology 306 (2013) 35– 39 39
the resulting excretion of BCP. Cho et al., 2007, suggest that chlor-
pyrifos and profenofos have the potential to inhibit the catalytic
activity of CYP2B6 and CYP2C19, which also metabolizes chlor-
pyrifos (Foxenberg et al., 2007). Essentially no CYP 2B6 activity
remained after in vitro chlorpyrifos or profenofos treatment, while
49 and 43 percent of the respective CYP2C19 activity remained
after chlorpyrifos and profenofos pretreatment of HLMs (Abass
et al., 2009). Chlorpyrifos was also sprayed in the Egyptian cotton
ﬁelds approximately 2 weeks prior to the beginning of the pro-
fenofos application period (Farahat et al., 2010, 2011). Therefore,
prior exposure to chlorpyrifos could inhibit CYPs 2B6 and 2C19
mediated metabolism of profenofos. This in turn might increase
inhibition of cholinesterase resulting in increased risk of neuro-
toxicity. Examining the interactive effects of serial exposures to
chlorpyrifos and profenofos experienced by Egyptian agricultural
workers will be critical to predicting the neurotoxic risks associated
with these real-world occupational exposures.
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